Clinical Trial

Intertrochanteric Femur Fracture Patients Who Receive Metformin With a Placebo

Enrolling by Invitation Early Phase 1
View on ClinicalTrials.gov →
Summary
The investigators central hypothesis is that metformin supplementation will be well-tolerated, safe, and provide patients with improved functional and muscle morphology outcomes following intertrochanteric femur fracture. The objectives will be tested in older adults that sustain a hip fracture and are randomized to receive a daily oral dose (1.5g daily) of metformin or a non-active placebo during 4 months of recovery following surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-10.
Trial Details
NCT Number NCT07179042
Lead Sponsor University of Utah
Conditions Intertrochanteric Femur Fracture, Muscle Atrophy
Enrollment 60 participants
Start Date 2025-09-04
Primary Completion 2030-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-29